#Biologic

Pras Francis, MD PhD

PrasFrancis

Let's talk about hydroxychloroquine (HCQ). tl;dr:1. There's a difference between biologic plausibility & early sign of clinical benefit.2. A standard must be met to show benefit-this hasn't.3. It can cause

The Tycoon Mindset

tycoonmindset05

Laurus Bio :Laurus Labs Acquires Richcore Lifesciences@unseenvalue @drprashantmish6 @punitbansal14 (thread) Laurus Labs has acquired 72.55% in Richcore at the valuation of Rs.340 crores- Laurus will be acquiring the stakes from

Jason Haas

jasonchaas

A little thread about this tweet that I feel like might illuminate our broader approach at Tablas Creek. The philosophy behind Biodynamics can seem awfully touchy-feely at times. Cycles of

reTALIAte

deoxdynamics

Carbon sequestration tl;dr outline pt 1 #EarthDay 1. CCU (the null case) – must be used properly2. Pumping underground – the OG, seems sketchy, ask a geophysicist3. Mineral carbonation –

Bassam Osman, MD

_bosman_

Where is my COVID 19 vaccine?More than 170 research teams racing.A thread about progress and concerns: First, the vaccine should pass through testing and trials:1.Preclinical: tested on animals, to test

TheRealRobtQuinlan

RCQ92130

1. CORONAVIRUS OUTBREAKTIME TO FREAK OUT, OR JUST IGNORE?The question here is simple: is this a human-engineered biological weapon specifically developed for mass death, that accidentally escaped containment, or is

Sandeep Vaheesan

sandeepvaheesan

1. A thread on how AbbVie, the manufacturer of Humira, abuses the patent system and an antitrust lawsuit challenging AbbVie's misconduct 2. Humira is a biologic medication used to treat

Jonathan Fuller

JonathanJFuller

This response by @mlipsitch to my @BostonReview #COVID19 piece (https://bostonreview.net/science-nature/jonathan-fuller-models-v-evidence) provides a fascinating (and philosophical) look inside epidemiological thinking at a time when understanding th

Bethan Goulden

bethangoulden

Next I'm listening to @StefanSiebert1 presenting on Psoriatic Arthritis - what are the management options in 2021? He highlights that new therapies mean we don't need to just treat it

robert rosencrans

rfrosencrans

In #RaceInABottle, Jonathan Kahn exhaustively documented these studies. Tiny, non-random samples extrapolated to millions. Bad statistics + bad theory. I prefer a different subgroup, repeatedly shown to have biologic import:

Amy C🍩🍩pes

coopesdetat

Latest @CDCMMWR looks at paediatric cases of #COVID19 in the US (n=2,572). Findings: Relatively few hospitalisations Fever, cough, SOB less prominent than adults Severe outcomes possible, 3 deaths this

Stefan Kertesz, MD

StefanKertesz

1/I have spent part of my time assisting VA and community efforts to address #homelessness in tandem with COVID19, not usually as “lead” but as “support”. I have some reflections

Maja Sercic

majasercic

This week marks years of biosimilar medicines in Europe. They have greately contributed to better access across Europe and beyond. Thread #biosimilars #access4all https://twitter.com/medicinesforEU/status/1381555506960027651 In Germany ,

Sarah Weller

_sarahweller

What are your go-to #ExerciseOncology and/or #CancerRehab papers that you use with your team (PT and Ex Phys), especially for those who are new to the field? I am creating

Laura Deming

LauraDeming

Here's a quick summary of interesting things to understand about aging biology, if you're new to the field: There are multiple, different definitions of aging. There are definitions around time

Robert Dickson

robertpdickson

The *alveolar poncho* (copyright @jopo899) theory of hyaline membrane deposition reminds me of a broader idea: maybe the more "pathognomonic" a finding is in a disease, the more likely it